Evidence map›Paper›PMID 40154862›Full record

ArticleBrain research2025

Reduction in [

Fariha Karim, Allyson Ngo, Tram B Danh, Brooke A Delaney, Christopher Liang, Geidy E Serrano, Thomas G Beach, Jogeshwar Mukherjee

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Increased Binding of [Synapse (New York, N.Y.) · 2026
    Article
  2. Assessment of [Biomolecules · 2025
    Article
  3. [Synapse (New York, N.Y.) · 2025
    Article
  4. Reduction in [Brain research · 2025
    Article
  5. Article
  6. Evaluation of [Receptors (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Fariha KarimPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA. Electronic address: fkarim1@uci.edu.
Allyson NgoPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA. Electronic address: allyson1@uci.edu.
Tram B DanhPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA. Electronic address: tbdanh@uci.edu.
Brooke A DelaneyPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA. Electronic address: badelane@uci.edu.
Christopher LiangPreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA. Electronic address: liangc@uci.edu.
Geidy E SerranoBanner Sun Health Research Institute, Sun City, AZ 85351, USA. Electronic address: geidy.serrano@bannerhealth.com.
Thomas G BeachBanner Sun Health Research Institute, Sun City, AZ 85351, USA. Electronic address: thomas.beach@bannerhealth.com.
Jogeshwar MukherjeePreclinical Imaging, Department of Radiological Sciences, University of California-Irvine, Irvine, CA 92697, USA. Electronic address: mukherjj@hs.uci.edu.

Funding

Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI REIMAN, ERIC MICHAEL · 2001 to 2020
$32.5M
National Brain and Tissue Resource for Parkinson's Disease and Related DisordersU24NS072026 · NINDS · BANNER SUN HEALTH RESEARCH INSTITUTE · PI BEACH, THOMAS G · 2011 to 2015
$7.8M
PET Imaging Agents for Nicotinic a4b2 ReceptorsR01AG029479 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI MUKHERJEE, JOGESHWAR · 2007 to 2017
$2.6M
PET Imaging agents for a4b2 Nicotinic ReceptorsRF1AG029479 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI CHRISTIAN, BRADLEY T, MUKHERJEE, JOGESHWAR · 2019 to 2020
$2.2M
Novel Tau-Targeted Radiohalogenated Agents for Alzheimer's DiseaseR01AG077700 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI Jogeshwar Mukherjee · 2024 to 2026
$2.1M
Evaluation of Monoamine Oxidase-A as a New Biomarker for Alzheimer's DiseaseR21AG079189 · NIA · UNIVERSITY OF CALIFORNIA-IRVINE · PI MUKHERJEE, JOGESHWAR · 2022 to 2022
$432k
NIA NIH HHS P30 AG019610NIA NIH HHS R01 AG029479NIA NIH HHS R01 AG077700NIA NIH HHS R21 AG079189NIA NIH HHS RF1 AG029479NINDS NIH HHS U24 NS072026
6 · The paper itself

Abstract

Nicotinic acetylcholinergic receptors (nAChRs), including the α4β2* subtype are involved in cognition, learning and memory and may be adversely affected in Alzheimer's disease (AD). In our efforts to consider translational use of [

Indexed as

Alzheimer DiseaseHippocampusReceptors, NicotinicAgedAged, 80 and overAmyloid beta-PeptidesAutoradiographyFemaleFluorine RadioisotopesHumansMaleMiddle AgedPlaque, AmyloidPositron-Emission TomographyPyridinesPyrrolesAmyloid beta-PeptidesFluorine Radioisotopesnicotinic receptor alpha4beta2nifenePyridinesPyrrolesRadiopharmaceuticalsReceptors, Nicotinictau Proteins[(125)I]IPPI[(18)F]Flotaza[(18)]NifeneAlzheimer’s diseaseHuman Aβ plaquesHuman TauNicotinic Receptors

Identifiers

PMID40154862
PMCPMC12245395

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.